Last reviewed · How we verify
Gardasill 9™ vaccine
Gardasil 9 is a recombinant vaccine that stimulates the immune system to produce antibodies against nine types of human papillomavirus (HPV) to prevent infection and associated cancers.
Gardasil 9 is a recombinant vaccine that stimulates the immune system to produce antibodies against nine types of human papillomavirus (HPV) to prevent infection and associated cancers. Used for Prevention of cervical cancer caused by HPV types 16, 18, 31, 33, 45, 52, 58, Prevention of anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, 58, Prevention of oropharyngeal cancer caused by HPV types 16, 18, 31, 33, 45, 52, 58.
At a glance
| Generic name | Gardasill 9™ vaccine |
|---|---|
| Sponsor | Imperial College London |
| Drug class | Recombinant virus-like particle vaccine |
| Target | Human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, 58 |
| Modality | Biologic |
| Therapeutic area | Oncology / Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains virus-like particles (VLPs) derived from the major capsid protein of nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58). These VLPs are non-infectious but immunogenic, triggering both humoral and cellular immune responses. The induced antibodies neutralize HPV before it can establish infection in epithelial tissues, thereby preventing HPV-related malignancies and benign lesions.
Approved indications
- Prevention of cervical cancer caused by HPV types 16, 18, 31, 33, 45, 52, 58
- Prevention of anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, 58
- Prevention of oropharyngeal cancer caused by HPV types 16, 18, 31, 33, 45, 52, 58
- Prevention of genital warts caused by HPV types 6, 11
- Prevention of vulvar and vaginal cancers caused by HPV types 16, 18, 31, 33, 45, 52, 58
Common side effects
- Injection site pain
- Injection site swelling
- Injection site erythema
- Headache
- Fever
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gardasill 9™ vaccine CI brief — competitive landscape report
- Gardasill 9™ vaccine updates RSS · CI watch RSS
- Imperial College London portfolio CI